SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy
about
Spinal muscular atrophy: development and implementation of potential treatmentsThe promise and perils of HDAC inhibitors in neurodegenerationDrosophila as an In Vivo Model for Human Neurodegenerative DiseaseSpinal muscular atrophy: diagnosis and management in a new therapeutic eraEpigenetic mechanisms underlying the pathogenesis of neurogenetic diseasesA Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy ControlsSpinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults.Investigational therapies for the treatment of spinal muscular atrophy.Developing therapies for spinal muscular atrophy.Strength Testing in Motor Neuron Diseases.Splice-Switching Therapy for Spinal Muscular Atrophy.Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy.Application of urine cells in drug intervention for spinal muscular atrophy.Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion.Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I.Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy.Treating pediatric neuromuscular disorders: The future is now.Solving the puzzle of spinal muscular atrophy: what are the missing pieces?
P2860
Q26861377-5ADA7017-8B26-4072-9080-32D9523AE30CQ28087539-37CF1F01-6E63-45FF-BE36-23C2968AC5C4Q28088777-461C1CC2-4022-46E0-B01E-1E62DD9F06C9Q34945009-5004B8E6-1B3A-4BB4-B0CC-AAE38985519EQ35340073-01591A8A-A6BC-40B3-AEEF-C4E8C48B0F20Q36205773-17BD71C4-4E28-4632-8802-2FB064A545A1Q37610527-7D32FD4C-1D14-4F68-BDA6-A3A074117C22Q38441280-B1EB3BE2-C26D-491F-BF8D-4516425FF9E1Q38546908-4C992613-143A-41C5-825C-4FBE34EE6E78Q38947721-E883A418-17C9-4451-8BE4-D1AC4054BE70Q39366631-2008F97E-7D29-4E22-9C9B-AD32468D54BBQ41110966-A300FF2C-867B-4CE6-A0EF-1F3A71EC45D8Q41672288-7824A148-2FC2-4962-8A24-E07A677B6B6CQ42100957-3702EEE3-0EAB-4C98-A507-CA9BE77B2A2AQ47794961-358187C7-68CD-4D50-A785-D2CFECAD02BAQ48144714-25924437-4332-4E4B-9FAF-4A73C7943526Q52756417-316823C6-DED1-4D9A-9439-19D822756F09Q54765007-7E6A3311-2EE0-42CB-A18E-CB84A411D60D
P2860
SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SMA valiant trial: a prospecti ...... s with spinal muscular atrophy
@en
SMA valiant trial: a prospecti ...... with spinal muscular atrophy.
@nl
type
label
SMA valiant trial: a prospecti ...... s with spinal muscular atrophy
@en
SMA valiant trial: a prospecti ...... with spinal muscular atrophy.
@nl
prefLabel
SMA valiant trial: a prospecti ...... s with spinal muscular atrophy
@en
SMA valiant trial: a prospecti ...... with spinal muscular atrophy.
@nl
P2093
P2860
P50
P356
P1433
P1476
SMA valiant trial: a prospecti ...... s with spinal muscular atrophy
@en
P2093
Bakri Elsheikh
Bernard LaSalle
Charles B Scott
Guy D'Anjou
Gyula Acsadi
Jo Anne Maczulski
John T Kissel
Mary K Schroth
Miriam Freimer
Project Cure Spinal Muscular Atrophy Investigators Network
P2860
P304
P356
10.1002/MUS.23904
P577
2014-02-01T00:00:00Z